The impact of tofacitinib on fatigue, sleep, and health‑related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials

Bartlett SJ, Bingham CO, van Vollenhoven R, Murray C, Gruben D, Gold DA, Cella D.
Arthritis Res Ther. 2022;24(1):83 doi: 10.1186/s13075-022-02724-x

This was an exploratory post hoc analysis of pooled data, from over 2000 patients in three Phase 3 studies of tofacitinib, which demonstrates an association between tofacitinib treatment and significantly greater improvements in fatigue, sleep, and health-related quality of life (HRQoL), compared with placebo. Affecting a large majority of patients with RA, fatigue is a common symptom of the disease and is detrimental to HRQoL. However, the clinical significance of this overwhelming, unpredicta...

Incidência Baseada em Idade (<65 vs ≥65 anos) de Infecções e Infecções Graves com Tofacitinib versus DMARDs biológicos nos Ensaios Clínicos em Artrite Reumatoide nos EUA e no Registro Corrona RA

Winthrop KL, Citera G, Gold D, Henrohn D, Connell CA, Shapiro AB, Shi H, Onofrei AM, Pappas DA, Schulze-Koops H.
Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992

Reports from clinical trials and the US Corrona RA registry showed that serious infection event (SIE) incidence was higher in older versus younger patients with RA receiving 10 mg BID of TOF and ADA, however, SIE risk was similar between age groups with TOF 5 mg BID and ADA. Data were collected from Phase II–IV tofacitinib studies, and the US Corrona RA registry. The clinical data set evaluated patients receiving TOF 5 and 10 mg BID versus TNFi (ADA/ETN) in RA patients aged ≥50 years. ...

Keywords: JAK, Tofacitinib, Clinical, Safety

Translated by: Igor Kos